Statistics from Altmetric.com
Question What is the comparative efficacy, risk of all-cause discontinuation and major side effects of antipsychotics used for the treatment of schizophrenia?
Outcomes The mean overall change in symptoms (primary outcome), all-cause discontinuation, weight gain, extrapyramidal side effects, prolactin increase, prolonged QT interval and sedation.
Design Systematic review and multiple-treatment meta-analysis.
Data sources Cochrane Schizophrenia Group's specialised register, MEDLINE, EMBASE, PsycINFO, CENTRAL and ClinicalTrials.gov were searched up to September 2012, supplemented by review of Food and Drug Administration and pharmaceutical company websites and reference lists of reviews.
Study selection and analysis Randomised controlled trials (single-blind at minimum) of 15 orally administered antipsychotic drugs used as monotherapy for the acute treatment of schizophrenia or related disorders (schizoaffective, schizophreniform or delusional disorder). Trials in stable patients, those with predominant negative symptoms, concomitant medical illnesses or treatment resistance were excluded. A multiple-treatment meta-analysis was performed. The standardised mean differences were calculated for continuous outcomes and ORs for …
Competing interests LC in the past 36 months was engaged in collaborative research with, or received consulting or speaking fees from Alexza, Alkermes, AstraZeneca, Avanir, Bristol-Myers Squibb, Eli Lilly, Envivo, Forest, Genentech, Janssen, Lundbeck, Merck, Mylan, Novartis, Noven, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda and Valeant.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.